Therapy Areas: Respiratory
BeOne Medicines expands US manufacturing with USD300m investment
23 July 2026 - Oncology company BeOne Medicines Ltd (NASDAQ:ONC) (HKEX:06160) (SSE:688235) announced on Thursday that it will invest USD300m to expand its flagship manufacturing and research and devel...
GSK's Jideytro (zidesamtinib) gains US approval for previously treated ROS1-positive NSCLC
23 July 2026 - Biopharmaceutical company GSK plc (LON:GSK) (NYSE:GSK) announced on Wednesday that the US Food and Drug Administration (FDA) has approved Jideytro (zidesamtinib), a ROS1 selective inhib...
Kelun-Biotech's Phase III study of sac-TMT in combination with pembrolizumab meets primary endpoint
15 July 2026 - Chinese pharmaceutical company Sichuan Kelun-Biotech Biopharmaceutical Co Ltd (HK:6990) announced on Tuesday that a Phase III clinical study (OptiTROP-Lung06) of its trophoblast cell-su...
AstraZeneca signs global licence deal with Dizal for lung cancer drug Zegfrovy
14 July 2026 - Biopharmaceutical company AstraZeneca PLC (STO: AZN; LON: AZN; NYSE: AZN) announced on Tuesday that it has agreed an exclusive worldwide licence with China's Dizal Pharmaceutical C...
Insilico initiates Rentosertib Phase III clinical trial for idiopathic pulmonary fibrosis
8 July 2026 - Clinical-stage biotechnology company Insilico Medicine (HKEX:3696) announced on Tuesday the initiation of the Phase III clinical trial for Rentosertib, its potentially first-in-class ora...
Genentech reports positive Phase III results for divarasib in KRAS G12C lung cancer
2 July 2026 - Biotechnology company Genentech, a member of the Roche Group (SIX: RO, ROG) (OTCQX: RHHBY), on Thursday reported positive Phase III results from the Krascendo 1 trial evaluating investig...